Disease Domain | Count |
---|---|
Neoplasms | 3 |
Nervous System Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Diagnostic radiopharmaceuticals | 1 |
Radionuclide Drug Conjugates (RDC) | 1 |
Monoclonal antibody | 1 |
Target- |
Mechanism DNA synthesis inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Class IIA HDACs inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Class IIA HDACs inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date21 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
99mTc-EC-metronidazole | Acute Ischemic Stroke More | Clinical |
TMP-195 ( Class IIA HDACs ) | Hypertension More | Preclinical |
TMP269 ( Class IIA HDACs ) | Hypertension More | Preclinical |
WO2023195834 ( CLEC4E )Patent Mining | Neurologic Manifestations More | Discovery |